Aptamer Group October 2018

19th October 2018.
This month data on our new improved delivery standard, webinar with Pall ForteBio, and interesting applications in targeted treatment and environmental detection of small molecules.

Following on from a successful Series A investment and lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to […]

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Portable Aptamer Based Sensor for Toxin Detection

9th August 2018 
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others

18th May 2018.

Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]

Aptamer Group Update: Quarter 3

Message from the CEO
I am pleased to report that the trends mentioned in the last Newsletter continue to improve. We can now boast successful delivery of aptamers to a range of small and large molecule targets for customers in academia, biotech and big Pharma. We are also moving towards integration of aptamers into devices and […]

  • Monoclonal data for aptamer selection in complex media

Aptamer Selection in Complex Media

25th August, 2017
Starting with the end in mind
The use of aptamers in point of care diagnostic devices, for monitoring drug dose levels or for use as therapeutics, requires functionality across a wide variety of conditions.

Aptamer selection starts in conditions optimised to promote aptamer/target interaction to identify the best target-binders. Subsequently, by introducing different pressures, we […]

Aptamer Group Update: Quarter 2

19th June 2017
 

Despite the current volatile environment for small businesses, Aptamer Group continues to grow and prosper. We are regularly delivering aptamers selected against small molecule and protein targets to our customers for a range of applications. The Aptamer Group is at an important stage of its evolution and in addition to collaborating with global […]